

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULES 3.10(1) AND 3.21 OF THE LISTING RULES AND TERMS OF REFERENCE OF COMMITTEES

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (“**Board**”) of directors (“**Director(s)**”) of TATA Health International Holdings Limited (the “**Company**”) hereby announces that Ms. Jiangju Qi (江菊琪) (“**Ms. Jiang**”) and Mr. Cai Tsz Yeung (蔡梓洋) (“**Mr. Cai**”) had tendered their resignation as independent non-executive Directors and had ceased to be members of each of the audit committee (the “**Audit Committee**”) and remuneration committee (the “**Remuneration Committee**”) of the Company with effect from 24 June and 26 June 2025, due to their other personal endeavours.

Ms. Jiang and Mr. Cai have confirmed that they does not have any disagreement with the Board and that there is no other matter relating to their resignation which needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to extend its gratitude to Ms. Jiang and Mr. Cai for their past valuable contributions to the Company during their tenure of office.

NON-COMPLIANCE WITH RULES 3.10(1) AND 3.21 OF THE LISTING RULES

Following the resignation of Ms. Jiang and Mr. Cai:

- (i) the number of independent non-executive Directors fell below the minimum number as required under Rule 3.10(1) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”);
- (ii) the number of members of the Audit Committee fell below the minimum number as required under Rule 3.21 of the Listing Rules; and

(iii) the number of members of each of the Audit Committee and the Remuneration Committee fell below the minimum number as required under the respective terms of reference of the Audit Committee and the Remuneration Committee.

As at the date of this announcement, the Company is still in the process of identifying a suitable candidate to fill up the vacancies for the positions of independent non-executive Director as well as member of each of the Audit Committee and the Remuneration Committee, and will endeavor to appoint any suitable candidate(s) so as to fulfill the minimum requirements under Rules 3.11 and 3.23 of the Listing Rules as well as the respective terms of reference of the Audit Committee and the Remuneration Committee within three months from 24 and 26 June 2025 respectively as soon as practicable.

The Company will make further announcement(s) in relation to such appointment(s) as and when appropriate in accordance with the Listing Rules.

By Order of the Board
TATA Health International Holdings Limited

Hong Kong, 27 June 2025

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and two independent non-executive Directors, namely, Mr. Wang Jian and Mr. Cai Tsz Yeung.